hVIVO (LON:HVO) Stock Passes Above 50-Day Moving Average - Here's Why

Key Points

• hVIVO plc shares have surpassed their 50-day moving average of GBX 10.46, indicating positive trading momentum, with the stock last trading at GBX 10.25.
• Analysts from Shore Capital and Peel Hunt have issued target prices of GBX 35 and GBX 21, respectively, while maintaining a "buy" and "add" rating on the stock.
• hVIVO plc specializes in human challenge clinical trials for vaccine and antiviral testing, serving various pharmaceutical and governmental clients with a market capitalization of £77.83 million.

Shares of hVIVO plc (LON:HVO - Get Free Report) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 10.46 ($0.14) and traded as high as GBX 10.50 ($0.14). hVIVO shares last traded at GBX 10.25 ($0.14), with a volume of 1,339,657 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Shore Capital reiterated a "buy" rating and issued a GBX 35 ($0.47) target price on shares of hVIVO in a report on Tuesday, July 22nd. Peel Hunt reiterated an "add" rating and issued a GBX 21 ($0.28) target price on shares of hVIVO in a report on Tuesday, July 29th.

hVIVO Stock Performance

The business has a 50 day simple moving average of GBX 10.46 and a 200 day simple moving average of GBX 14.66. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company has a market capitalization of £77.83 million, a PE ratio of 4.54 and a beta of 0.97.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.